Comparative Pharmacology
Head-to-head clinical analysis: ALBUTEROL SULFATE IPRATROPIUM BROMIDE versus DETROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBUTEROL SULFATE IPRATROPIUM BROMIDE versus DETROL.
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE vs DETROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albuterol sulfate is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle. Ipratropium bromide is an anticholinergic agent that inhibits muscarinic acetylcholine receptors, reducing bronchoconstriction and mucus secretion.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
2 inhalations (each inhalation delivers 90 mcg albuterol sulfate and 18 mcg ipratropium bromide) four times daily via oral inhalation; maximum 12 inhalations in 24 hours.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
None Documented
None Documented
Albuterol: terminal half-life 3.8-6 hours; Ipratropium: terminal half-life 1.5-4 hours (clinical: twice-daily dosing for chronic therapy).
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Albuterol: renal excretion of unchanged drug and metabolites (~60-70% as metabolites, ~10-20% unchanged); Ipratropium: primarily renal (~50% unchanged), with biliary/fecal excretion accounting for minor amounts.
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Category A/B
Category C
Anticholinergic
Anticholinergic